Cevimeline Information & Cevimeline Links at HealthHaven.com

Cevimeline
Systematic (IUPAC) name
	2-methyspiro (1,3- oxathiolane- 5,3) quinuclidine
Identifiers
CAS number	107233-08-9
ATC code	N07AX03
PubChem	83898
DrugBank	APRD00224
ChemSpider	75707
Chemical data
Formula	C10H17NOS
Mol. mass	489.565 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	?
Protein binding	< 20%
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	C
Legal status	Rx only
Routes	Oral
	(what is this?) (verify);

Cevimeline is a parasympathomimetic and muscarinic agonist,^[1] with particular effect on M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

[edit] Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

[edit] Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. ^[2]

[edit] References

^ Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277. http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369.
^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

[edit] External links

Evoxac website

[pmid15234277-0] Ono M, Takamura E, Shinozaki K, et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. doi:10.1016/j.ajo.2004.02.010. PMID 15234277. http://linkinghub.elsevier.com/retrieve/pii/S0002939404001369.

[1] [1] MedicineNet: Cevimeline. Accessed 10/12/2007

[1]

[2]

Contents

[edit] Mechanism of action

[edit] Side effects

[edit] References

[edit] External links